HHS-OIG Foregoes Sanctions on Drug Manufacturer for Providing Free Drugs to Patients Waiting for Insurance Authorization
Highlights
HHS-OIG declined to impose administrative sanctions on a drug manufacturer for providing a drug at no charge, for a limited time, to patients experiencing delays in their insurance approval process
The agency determined the arrangement posed little risk of overutilization or undue influence on prescribing patterns because healthcare providers would be unaware when prescribing that a patient may receive the drug at no charge
This seems to be part of a trend of leniency by the agency when there is no risk of overutilization or undue influence
The Office of Inspector General of the U.S. Department of Health and Human Services (HHS-OIG) issued Advisory Opinion No. 23-02 on Feb. 28 regarding sanctions against a manufacturer for its program that provides a particular specialty drug for free, for a limited time, to patients who experience a delay in their insurance approval process for the manufacturer's drug.
Keep Up to Date in a Changing World
